Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK3 | P49761 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3992930 | 1.00 | MAPK14 (0.75) | MAPK14CYP3A4BRAFCDK9DYRK1A | |
| SCHEMBL29594821 | 0.91 | MAPK14 (0.63) | MAPK14CDK9DYRK1ADYRK2CSNK1E | |
| SCHEMBL4069771 | 0.91 | MAPK14 (0.63) | MAPK14CDK9DYRK1ADYRK2CSNK1E | |
| Ralimetinib SCHEMBL4069195 | 0.90 | MAPK14 (0.73) | MAPK14CYP3A4BRAF | |
| Ralimetinib SCHEMBL16347433 | 0.90 | MAPK14 (0.73) | MAPK14CYP3A4BRAF | |
| Ralimetinib SCHEMBL29437771 | 0.90 | MAPK14 (0.73) | MAPK14CYP3A4BRAF | |
| Ralimetinib SCHEMBL29395970 | 0.90 | MAPK14 (0.73) | MAPK14CYP3A4BRAF | |
| SCHEMBL29594861 | 0.86 | MAPK14 (0.75) | MAPK14 | |
| SCHEMBL4071410 | 0.86 | MAPK14 (0.75) | MAPK14 | |
| SCHEMBL29593474 | 0.85 | MAPK14 (0.76) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114748622-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-114732910-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-114748622-A | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | 弗尔康医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114732910-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |